Shamburg News · 8-K filed Nov 12, 2026, 8:25 AM EST
SpyGlass Pharma Reports Q3 2026 Net Loss of $24.3 Million, Completes AVS Acquisition
SGP · SpyGlass Pharma, Inc.
- Earnings
- Acquisition
- Other event
- Materiality: high
SpyGlass Pharma reported a net loss of $24.3 million, or $(0.73) per basic and diluted share, for the quarter ended September 30, 2026, compared with $9.8 million, or $(4.53) per share, a year earlier. Research and development expenses were $10.0 million and general and administrative expenses were $16.2 million for the quarter. The company also reported cash, cash equivalents and short-term investments of $215.8 million, acquired Advanced Vision Science, Inc. for approximately $13 million in cash in October 2026, and completed first implantations in the first-in-human study of its BIM-DRS.
Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, accession 0001778922-26-000055.
Written from the filing by Shamburg Markets. Figures are as reported by the company.